WO2010081443A3 - Formes galéniques d'inhibiteurs de tyrosine kinase - Google Patents

Formes galéniques d'inhibiteurs de tyrosine kinase Download PDF

Info

Publication number
WO2010081443A3
WO2010081443A3 PCT/CZ2010/000002 CZ2010000002W WO2010081443A3 WO 2010081443 A3 WO2010081443 A3 WO 2010081443A3 CZ 2010000002 W CZ2010000002 W CZ 2010000002W WO 2010081443 A3 WO2010081443 A3 WO 2010081443A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
kinase inhibitors
tyrosine kinase
inhibitors
medicaments
Prior art date
Application number
PCT/CZ2010/000002
Other languages
English (en)
Other versions
WO2010081443A2 (fr
Inventor
Vladimir Kral
Josef Jampilek
Jaroslav Havlicek
Hana Brusova
Tomas Pekarek
Original Assignee
Zentiva, K.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, K.S. filed Critical Zentiva, K.S.
Publication of WO2010081443A2 publication Critical patent/WO2010081443A2/fr
Publication of WO2010081443A3 publication Critical patent/WO2010081443A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des co-cristaux d'inhibiteurs de tyrosine kinases, spécialement de mésylate d'Imatinib, se sont révélés une forme adaptée d'API dans des formes galéniques, classiques comme à libération contrôlée, pour des médicaments de seconde génération. Des complexes d'inhibiteurs de kinase avec des polysaccharides fonctionnalisés forment des dispersions solides adaptées aux applications pharmaceutiques.
PCT/CZ2010/000002 2009-01-13 2010-01-13 Formes galéniques d'inhibiteurs de tyrosine kinase WO2010081443A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZPV2009-8 2009-01-13
CZ20090008A CZ20098A3 (cs) 2009-01-13 2009-01-13 Lékové formy inhibitoru tyrosinových kináz

Publications (2)

Publication Number Publication Date
WO2010081443A2 WO2010081443A2 (fr) 2010-07-22
WO2010081443A3 true WO2010081443A3 (fr) 2011-10-27

Family

ID=42338099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000002 WO2010081443A2 (fr) 2009-01-13 2010-01-13 Formes galéniques d'inhibiteurs de tyrosine kinase

Country Status (2)

Country Link
CZ (1) CZ20098A3 (fr)
WO (1) WO2010081443A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7006995B2 (ja) 2012-01-13 2022-01-24 エックススプレイ ファーマ パブリーク・アクチエボラグ 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2009570A3 (cs) * 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
CN102188365B (zh) * 2011-05-11 2012-12-05 中山大学 一种难溶性药物共晶固体分散体及其制备方法
CA2876539A1 (fr) 2012-06-15 2013-12-19 Basf Se Cristaux a plusieurs composants comprenant du dasatinib et des agents de formation de cocristaux choisis
EP2864313A1 (fr) 2012-06-22 2015-04-29 Basf Se Cristaux multicomposants comprenant du mésilate d'imatinib et des agents de co-cristallisation choisis
WO2014016848A2 (fr) * 2012-07-24 2014-01-30 Laurus Labs Private Limited Formes solides d'inhibiteurs de tyrosine kinase, procédé pour leur préparation et leur composition pharmaceutique
CA2887540A1 (fr) * 2012-10-19 2014-04-24 Basf Se Systeme cristallin multicomposant comprenant du nilotinib et des formateurs de co-cristal selectionnes
CN103800334B (zh) * 2012-11-07 2016-12-21 北大方正集团有限公司 甲磺酸伊马替尼的药物组合物及其制备方法
WO2015011120A2 (fr) 2013-07-25 2015-01-29 Basf Se Sels de dasatinib se présentant sous forme cristalline
JP6370377B2 (ja) * 2013-07-25 2018-08-08 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 非晶質形態のダサチニブの塩
US9278955B2 (en) * 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
EP2937346A1 (fr) * 2014-04-24 2015-10-28 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Co-cristaux de lapatinib
WO2016058081A1 (fr) 2014-10-16 2016-04-21 Apotex Inc. Formes solides du chlorhydrate de nilotinib
US20180000827A1 (en) 2014-12-19 2018-01-04 Synthon B.V. Pharmaceutical composition comprising gefitinib
PT109445B (pt) * 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
IT201700006157A1 (it) 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristalli di un composto antitumorale
IT201700006145A1 (it) 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristallo di un composto antitumorale
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
EP4093379A1 (fr) 2020-01-24 2022-11-30 Nanocopoeia LLC Dispersions solides amorphes de dasatinib et leurs utilisations
WO2021155254A1 (fr) 2020-01-31 2021-08-05 Nanocopoeia, Llc Microparticules de nilotinib amorphe et leurs utilisations
WO2021222739A1 (fr) 2020-04-30 2021-11-04 Nanocopoeia, Llc Comprimé à désintégration orale comprenant une dispersion solide amorphe de nilotinib
WO2022000265A1 (fr) * 2020-06-30 2022-01-06 天津理工大学 Cocristaux d'axitinib et d'acide glutarique, et leur procédé de préparation
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
CN115417812B (zh) * 2022-08-05 2024-04-05 天津大学 一种阿西替尼-烟酰胺共晶及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027600A2 (fr) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Compositions d'imatinib
WO2008112722A2 (fr) * 2007-03-12 2008-09-18 Dr. Reddy's Laboratories Ltd. Mésylate d'imatinib
EP2000139A1 (fr) * 2007-06-07 2008-12-10 Novartis AG Formes amorphes stabilisées du mésylate de l'imatinib

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027600A2 (fr) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Compositions d'imatinib
WO2008112722A2 (fr) * 2007-03-12 2008-09-18 Dr. Reddy's Laboratories Ltd. Mésylate d'imatinib
EP2000139A1 (fr) * 2007-06-07 2008-12-10 Novartis AG Formes amorphes stabilisées du mésylate de l'imatinib

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENI ET AL: "Cyclodextrin/imatinib complexation: Binding mode and charge dependent stabilities", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 30, no. 2, 26 January 2007 (2007-01-26), pages 167 - 174, XP005738249, ISSN: 0928-0987, DOI: DOI:10.1016/J.EJPS.2006.10.008 *
LEUNER C ET AL: "Improving drug solubility for oral delivery using solid dispersions", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 50, no. 1, 3 July 2000 (2000-07-03), pages 47 - 60, XP004257179, ISSN: 0939-6411, DOI: DOI:10.1016/S0939-6411(00)00076-X *
PEDDY VISHWESHWAR ET AL: "Pharmaceutical Co-Crystals", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 95, no. 3, 1 January 2006 (2006-01-01), pages 499 - 516, XP002492464, ISSN: 0022-3549, DOI: DOI:10.1002/JPS.20578 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7006995B2 (ja) 2012-01-13 2022-01-24 エックススプレイ ファーマ パブリーク・アクチエボラグ 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法

Also Published As

Publication number Publication date
CZ20098A3 (cs) 2010-07-21
WO2010081443A2 (fr) 2010-07-22

Similar Documents

Publication Publication Date Title
WO2010081443A3 (fr) Formes galéniques d'inhibiteurs de tyrosine kinase
WO2011031896A3 (fr) Inhibiteurs de pi3 kinase et leurs utilisations
GEP20197011B (en) Heteroaryl compounds for kinase inhibition
WO2008138755A3 (fr) Compositions pharmaceutiques pour des médicaments solubles de façon médiocre
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
WO2014096388A3 (fr) Nouveaux dérivés de benzimidazole en tant qu'inhibiteurs de la kinase
IN2012DN02469A (fr)
WO2010123919A3 (fr) Inhibiteurs pipéridiniques de la janus kinase 3
EP2251038A4 (fr) Dispersion solide, compositions pharmaceutiques comprenant celle-ci, et procédés de production associés
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
SG171542A1 (en) Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin
WO2012122383A3 (fr) Inhibiteurs de pi3 kinase et leurs utilisations
WO2010120994A3 (fr) Composés d'uréido-aryl-pyrimidine et de carbamoylaryl-morpholino-pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi-3, et leur synthèse
WO2012122011A3 (fr) Amino-quinoléines en tant qu'inhibiteurs de kinase
WO2011073341A3 (fr) Dispersions de polymères
WO2011106248A3 (fr) Inhibiteurs triméthoxyphényles de la tyrosine kinase
MY161461A (en) Akt and p70 s6 kinase inhibitors
WO2011056511A3 (fr) Stimulateurs de la guanylate cyclase soluble à base de 4,6-diaminopyrimidine
WO2014076712A3 (fr) Dispersion solide de chlorhydrate de lurasidone
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
WO2009114461A3 (fr) Formes pharmaceutiques d'angiotensine (1-7) et leur utilisation
WO2011056741A3 (fr) Sphéroïdes de médicament enrobés et utilisations de ceux-ci pour éliminer ou réduire des affections telles que le vomissement et la diarrhée
SG10201402867TA (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
WO2014043252A3 (fr) Hydroxypyridones, hydroxypyrimidinones et hydroxypyridazinones thérapeutiques

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10714557

Country of ref document: EP

Kind code of ref document: A2